Sensory barrage stimulation in the treatment of elbow spasticity: a crossover double blind randomized pilot trial by Slovak, Martin et al.
Sensory barrage stimulation in the treatment of elbow 
spasticity: a crossover double blind randomized pilot trial
SLOVAK, Martin, CHINDO, Joseph, NAIR, Krishnan Padmakumari 
Sivaraman, REEVES, Mark L., HELLER, Ben and BARKER, Anthony T.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/11757/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
SLOVAK, Martin, CHINDO, Joseph, NAIR, Krishnan Padmakumari Sivaraman, 
REEVES, Mark L., HELLER, Ben and BARKER, Anthony T. (2016). Sensory barrage 
stimulation in the treatment of elbow spasticity: a crossover double blind randomized 
pilot trial. Neuromodulation: Technology at the Neural Interface, 19 (2), 220-226. 
Repository use policy
Copyright © and Moral Rights for the papers on this site are retained by the 
individual authors and/or other copyright owners. Users may download and/or print 
one copy of any article(s) in SHURA to facilitate their private study or for non-
commercial research. You may not engage in further distribution of the material or 
use it for any profit-making activities or any commercial gain.





Objective: To assess the feasibility of using a novel form of multi-channel 
electrical stimulation, termed Sensory Barrage Stimulation (SBS) for the 
treatment of spasticity affecting the elbow flexor muscles and to compare this 
with conventional single-channel TENS stimulation.   
Materials and methods: altogether 10 participants with spasticity of the flexor 
muscles of the elbow of grade 2 or above on the Modified Ashworth Scale 
(MAS) were recruited to this crossover double blind randomized trial. The 
participants received two intervention sessions (SBS and TENS), one week 
apart in a randomised order.   Both interventions were applied over the triceps 
brachii on the affected arm for a duration of 60 minutes. Spasticity was 
measured using the MAS. Secondary outcome measures were self-reported 
change in spasticity, measured on a Visual Analogue Scale (VAS, 0-100), and 
therapist-rated strength of elbow extension (SEE) and strength of elbow flexion 
(SEF). Measurements were taken immediately before each intervention was 
applied, immediately after the intervention, and one hour after the intervention.    
Results: Immediately after stimulation spasticity showed a significant reduction 
for both TENS and SBS groups assessed by MAS -0.9 ± 0.2 vs. -1.1 ± 0.2 and 
by VAS -15 ± 3 vs. -31 ± 8. For SBS this improvement in MAS was still present 
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at one hour after the stimulation, but not for TENS.  Altogether seven SBS 
responders and four TENS responders were identified.  
Conclusions: This study demonstrates the feasibility and practicality of 
applying the new concept of Sensory Barrage Stimulation. Promising results 




Spasticity is a disorder of sensorimotor control, resulting from an upper motor 
neurone (UMN) lesion and presenting as the intermittent or sustained 
involuntary activation of muscles [1]. It can interfere with functional recovery and 
lead to contractures, which may impact significantly on patients’ everyday living 
activities. Botulinum toxin, Intrathecal Baclofen Therapy and commonly used 
pharmacological agents such as Baclofen, Tizanidine, Dantrolene, or Diazepam 
are used for the treatment of spasticity [2]. However, in some patients spasticity 
might be resistant to oral treatment or the therapy might not be well tolerated 
due to side effects such as weakness, dizziness and drowsiness. In particular 
use of oral pharmacological in focal limb spasticity seems to be ineffective [3]. 
Non-pharmacological approaches such as muscle vibration, extracorporeal 
shock wave therapy and various forms of magnetic or electrical stimulation have 
been tried for the treatment of spasticity [2], but there is insufficient evidence to 
justify using these modalities routinely [4]. This paper focuses on the use of two 
different types of electrical stimulation: a conventional type of transcutaneous 
electrical nerve stimulation (TENS) and a novel concept of Sensory Barrage 
Stimulation (SBS) as described below.  
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TENS typically uses a single pair of electrodes placed on the skin over 
the affected site and delivers a continuous stream of repeated electrical stimuli 
at an amplitude below  that which causes muscle contraction.  TENS applied to 
the sural nerve was reported to reduce spasticity in patients with hemiplegia [5]. 
Similar effects were noted in patients with spinal cord injury immediately after 
60 min of 100 Hz stimulation using TENS [6]. Several long term studies showed 
promising results [7, 8], but a study with multiple sclerosis patients did not 
demonstrate a reduction in spasticity [9] although TENS did help to reduce pain.  
It has been proposed that applying TENS to peripheral sensory nerves 
reduces spasticity by modulating either spinal inhibitory circuits or those of the 
central nervous system [6].  
We hypothesise that the effects of TENS on spasticity can be enhanced 
with a new form of stimulus that has two distinct features. Firstly, we 
hypothesise that it would be beneficial to stimulate a larger area of skin and 
hence stimulate more sensory fibres. This could be achieved by using larger 
electrodes. However, the stimulus current density would not be guaranteed to 
be distributed evenly over the electrode and, in particular, would be expected to 
be greater at the edges of the electrode [10]. Instead therefore, we used a 
modified 64-channel, constant current, programmable electrical stimulator, 
5 
 
previously developed for use in foot drop therapy [11], which allowed us to 
deliver the stimuli evenly over a larger area compared to TENS. Our second 
hypothesis was that participants may become habituated to the constant 
stimulation delivered by TENS between two fixed sites, and thus the stimulus 
becomes less effective over time. The mechanisms underlying recovery after 
neural injury, such as stroke, presumably involve a ‘rewiring’ plasticity 
processes [12]. Areas of the cortex can  take over functionality in response to 
an injury or as a natural process following learning. It has been shown that 
attention plays an important role in learning and hence in plasticity [13]. 
Therefore stimulation capable of producing ‘interesting’ (or ‘salient’) sensations, 
delivered via multiple electrodes (as opposed to a single  electrode with a 
monotonic stimulus delivery) may improve neuroplasticity effects due to the 
direction of attention to the salient stimulus. Further, reciprocal inhibition of 
antagonist muscle groups plays an important role in voluntary movement in 
healthy subjects. A deficiency in these mechanisms is likely to contribute to 
spasticity and has been the focus of some studies [14, 15]. It has been noted 
that patterned sensory stimulation is more effective in inducing plasticity in this 
reciprocal 1a sensory inhibition in comparison to monotone stimulation [16]. 
Therefore to further enhance the effects of multi-electrode stimulation we have 
employed an intermittent pattern of stimuli which mimics a sensation of 
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movement (stroking) [17] over the electrode array. We have termed this generic 
type of stimulation “Sensory Barrage Stimulation” (SBS). 
The aim of this pilot trial was to assess the feasibility of using SBS for 
the treatment of spasticity affecting the elbow flexor muscles and to compare 
this with conventional TENS stimulation applied between two electrodes.  
Methodology 
The study was approved by the regional ethics committee. Ten 
participants with spasticity of the flexor muscles of the elbow were recruited 
from neurology clinics at the Royal Hallamshire Hospital, Sheffield. 
The study was designed as a crossover double-blind randomized trial. 
Potential participants were provided with an information sheet and contacted 
two weeks later. If they decided to participate in the study they were invited to 
attend two study visits, spaced one week apart. At the first visit the participants 
were screened for inclusion and exclusion criteria and gave their informed 
consent. The inclusion criteria were: (1) male or female, age ≥18; (2) spasticity 
of the flexor muscles of the elbow (of Grade 2 or more on the Modified 
Ashworth Scale (MAS) [18]);  (3) neurologically stable for at least 6 months. The 
exclusion criteria were (1) a cognitive impairment that would interfere with their 
ability to comply with the experimental protocol or provide informed consent; (2) 
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any dermatological, rheumatologic or orthopaedic complications that might 
interfere with the stimulation of the affected arm;  (3) pre-existing severe 
cardiovascular disease; active cancer or renal disease; end stage pulmonary or 
cardiovascular disease; psychiatric illness including severe alcohol or drug 
abuse and depression; (4) severe tactile hypersensitivity as assessed by a non-
stimulation approach; and (5) those who had participated in other spasticity-
related studies. 
The eligible participants were randomised into one of two groups using 
computer-generated random numbers provided by a colleague  who was not 
involved in the data collection or analyses. Group 1 underwent SBS at their first 
study visit and TENS one week later. Group 2 underwent the same 
interventions in the opposite order, TENS first and SBS one week later. Only 
the experimenter who applied the stimulation, and who was not involved in data 
collection, knew the allocation sequence and thus knew which group each 
participant was allocated to and what intervention was delivered. Both 
interventions were applied for 60 minutes at a stimulus level just below the 
threshold for motor contraction. The intensity was gradually increased until a 
visible motor contraction was observed and then decreased to a level when it 
just ceased. If this level could not be achieved due to discomfort, then the 
strongest comfortable intensity was used.  
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SBS was delivered using  a modified 64-channel, constant current, 
programmable electrical stimulator. During the stimulation, the 64-channel 
stimulator was connected to a laptop and controlled via software produced in-
house.  The electrodes consisted of an 8x8 array of 8x8 mm square electrodes 
(with a 3 mm gap between each electrode) on a flexible printed circuit board. 
The overall dimension of the electrode array was 91x91 mm. An adhesive 
hydrogel sheet (ST GEL-high impedance grade SCBZAB-05M, Sekisui Plastics, 
Japan) with a resistivity of 1.3 kΩ*m and a thickness of 0.5 mm was adhered to 
the surface of the electrode array to act as the interface between the electrodes 
and the skin [19].. The design of the moving SBS pattern is shown in Figure 1.  
The electrode array was divided virtually into eight strips (each eight electrodes 
long). Each individual strip was activated for approximately 0.3 s with a burst of 
fifteen 250 µs current pulses at 50 Hz applied simultaneously to all electrodes in 
the strip. The next strip was then activated while the previous one was 
deactivated and this cycle was repeated until the last strip had completed its 
sequence of stimulation pulses.  This was followed by a pause of approximately 
2.5 s, when no current was delivered.  In combination this provided a pattern 
mimicking stroking from the proximal to the distal part of the arm. The pulse 
repetition rate of 50 Hz and the on/off periods were chosen because they gave 
the most convincing subjective sensation of stroking in pilot studies. All 
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electrodes delivered the same current and this was globally adjusted by the 
operator according to each individual participant’s motor threshold.    
TENS intervention was delivered using a commercial stimulator (Multi-
TENS, NeuroTrac, VerityMedical Ltd., UK). The parameters of the stimulation 
were set as a pattern of stimulation with pulse repetition of 100 Hz according to 
previous studies [6, 9, 16] and 250 µs pulse width with an “on phase” of 6 s 
including a 1 s rising edge ramp, a 1 s falling edge ramp,  and a 4 s “off phase” 
in which no current was delivered. To mimic the physical setup of SBS and to 
blind participants to which system was being applied, the cathode electrode 
(50x50 mm, VS50, VerityMedical Ltd., UK) was placed centrally underneath the 
array setup used for SBS stimulation, which was not activated during the TENS 
stimulation. This single electrode was connected to the TENS stimulator and the 
participant was not aware that was being applied. The setup visually identical 
for both interventions.  
The arrays (both for SBS and TENS) were placed on the middle of the 
triceps brachii on the dorsal aspect of the affected arm and strapped with a 
cohesive bandage to ensure consistent contact between the electrode and the 
skin (Figure 2). An anode electrode (100x50 mm, VS10050, VerityMedical Ltd., 
10 
 
UK) was placed proximally on the deltoid muscle of the shoulder on the same 
arm for both types of stimulation.   
The assessment protocol was the same for both the SBS and TENS 
study visits.  Participants were assessed before the stimulation was applied, 
immediately after the stimulation finished, and a further one hour after the 
stimulation finished. The clinical assessments described below were performed 
by the same clinician throughout the study. The clinician was blinded as to the 
intervention applied. This was achieved by removing the electrodes and 
equipment before the clinician was invited into the room to perform the 
assessments. The clinician recorded the assessment data in the participant’s 
study file.  The participants were informed that the study was investigating two 
different techniques for stimulating sensory nerves. The primary outcome 
measure was the MAS at the elbow, as assessed by the clinician as follows. 
The participant laid in a supine position with the arm supported, in a neutral 
position and the forearm in supination. The arm was passively flexed and then 
extended over a period of one second. This was repeated several times and the 
resistance to the extension was scored according to the MAS [20]. The 
secondary outcome measures used were 1.  strength of elbow extension (SEE) 
and flexion (SEF) based on Medical Research Council (MRC) grades [21] and 
2. a Visual Analogue Scale (VAS) of the perceived effect on spasticity rated by 
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the participant on a 13 cm line with the left end being the worst imaginable 
spasticity and right end being no spasticity. The VAS was subsequently 
normalised to a percentage where 0% represented the participant experiencing 
no spasticity and 100% represented the worst spasticity they could envisage.  
The participants who had a reduction in spasticity of at least one grade on the 
MAS when combined with a 30% decrease of spasticity relative to the baseline 
value on the VAS were considered to be responders.  
Analyses of the data were performed by a researcher not involved in 
the data collection. Baseline data were compared with those immediately after 
and one hour after the interventions using the Wilcoxon Signed Rank test 
(chosen because of the non-parametric nature of the outcome measures). 
TENS and SBS were compared using the Mann-Whitney U test at each 
assessment period. GraphPad Prism version 6.00 for Windows (GraphPad 
Software, San Diego California USA) was used for the analyses. All analyses 
were performed using intention to treat.  
Results 
We approached 17 patients, of whom 10 consented to take part in the 
study. Four others did not wish to participate: two were not able to participate 
due to problems with transport and one had an implanted device - an exclusion 
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criteria for the study . The study flow diagram is shown on Figure 3. Among the 
10 recruited participants there were five men and five women. Their age ranged 
from 18 to 65 years (40±17 years, mean±SD). The aetiology of spasticity was: 
cerebral palsy (4), stroke (3), traumatic brain injury (2) and multiple sclerosis 
(1). The duration of spasticity symptoms varied from six to 38 years. All 
tolerated the interventions well and completed the study, giving a 100% 
retention rate. 
Across all participants, the average current during a pulse was in the 
range of 8 to 16 mA with a mean of 10.9±2.2 mA (mean ± SD) for TENS 
(excluding the ramp period) and the average total current from the eight 
simultaneously activated SBS electrodes was in the range of 7.2 to 15.2 mA 
with a mean of 12.9±2.5 mA. 
Individual clinical outcome measures in each participant for spasticity, 
MAS and VASare shown in Figure 4.  Immediately after TENS there were 2/10 
responders and after SBS 6/10 responders, as defined in the methodology 
(Table 1). One hour after the interventions, these effects persisted in both of the 
TENS responders and in four of the SBS responders. However two additional 
TENS and one additional SBS participants fulfilled the criteria of clinically 
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significant improvement at this point and were therefore also considered as 
responders .  
The overall comparison of both interventions is summarised in Table 2. 
Immediately after stimulation the MAS showed a significant reduction for both 
TENS (p = 0.016) and SBS (p = 0.0039). There was a reduction of at least one 
MAS grade in seven TENS participants and nine SBS participants at the end of 
stimulation (Figure 4). The VAS also reduced significantly for both TENS (p = 
0.027) and SBS (p = 0.0059).  At one hour after the stimulation with TENS, 
there was no significant change in MAS compared to baseline. However, the 
patients’ perception as recorded with VAS continued to show a significant 
change (Table 2). One hour after SBS a significant reduction in spasticity both 
on the MAS and VAS was noted. There was no statistically significant difference 
between the interventions in any of the outcomes (Table 2). However, a trend 
was noted for a better response with SBS at one hour after the stimulation 
compared to TENS and this was close to significance (p = 0.063). The order of 
interventions was randomised and no significant difference was found between 
Group 1 (SBS first) and Group 2 (TENS first) in baseline results for either MAS 
or VAS, with the exception of participant #7 (Group 1, SBS responder).  There 
were no significant changes in the MRC grades of elbow flexion and extension 
with TENS and SBS (Table 2). The adverse events reported after SBS were 
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one case of muscle spasm and one of an ache localised over the triceps 
muscle. One participant reported experiencing a sensation of pins and needles 
over his little finger after TENS.   
Discussion 
Among 17 potentially eligible subjects, 10 participated in this study and 
all completed the trial protocol. All participants tolerated the interventions well 
and there were no significant adverse events. This study demonstrated the 
feasibility and practicality of using SBS; a new type of electrical stimulation. 
TENS stimulation below motor threshold, has been reported to have 
positive effects on spasticity in spinal cord injury [6], in chronic hemiplegia after 
stroke [5, 22] and in multiple sclerosis [8]. Although optimal TENS stimulation 
parameters have not been determined, 100Hz seems to be effective [5, 8].  In 
our study TENS significantly reduced spasticity as measured on MAS 
immediately after 60 minutes of stimulation. Although the effect seems to have 
persisted in some of the participants after one hour, this did not achieve 
significance (p>0.063)  in this small sample size group (n=10).  
To try to enhance the effects of conventional TENS we have created 
the novel concept of Sensory Barrage Stimulation, which allows us to deliver 
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stimuli at multiple sites and with spatio-temporal patterns which give the 
sensation that the stimuli are moving over the skin, both of which may aid in 
producing a greater subjective sensory input. In this study, SBS continued to 
show a significant response both immediately after and one hour after 
stimulation (Table 2).  
A combination of improvement in both MAS and in the participants’ VAS 
outcome measures was assumed to be a clinically robust way of evaluating the 
effects of stimulation and this identified seven SBS responders compared to 
four in the TENS group (Table 1). Although the Wilcoxon Signed Rank test 
showed significant differences in MAS and VAS immediately after TENS, SBS 
showed greater differences in mean values and 95% CI (Table 2) compared to 
baseline with a  that persisted for at least one hour after stimulation. These 
results are not definitive, but are suggestive of our hypothesis that SBS is better 
than TENS in reducing spasticity. 
Extension and flexion strength did not show a significant improvement, 
although this could possibly be explained by already high grades, indicating a 
low severity in muscle weakness, with 6 out of 10 participants displaying normal 
extension strength (MRC grade of 5) throughout the full test procedure with both 
TENS and SBS. 
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SBS might also be beneficial in rehabilitation techniques where 
peripheral electrical nerve stimulation has been proposed as a method to 
enhance motor or tactile sensation deficits[7, 22]  as well as in combination with 
standard rehabilitation programmes [23, 24]. Support for TENS over Baclofen 
was also noted previously with similar marginal decrease in MAS [25], although 
decrease of about 1 unit maybe of only minor clinical significance. This study 
investigated only the short-term effects of stimulation. However, since the 
effects of SBS lasted at least an hour after the intervention, this could potentially 
be an opportunity for occupational therapists and physiotherapists to provide 
further therapy and assessments of other contractures. Thus this enhanced 
transient effect could be the major benefit of SBS, specifically for focal spasticity 
when other treatments could not be used or are not effective... If patients are 
more likely to benefit from several sessions it may be preferable  if they are 
managed at home, as this would be both more cost-effective and convenient for 
the patient. We think that this should be practical both for SBS and TENS. 
Although patients tolerated SBS well and there are no know side effects of this 
type of therapies, further investigations would be required to assess the 
tolerability and acceptability of several sessions of stimulation. Future studies 
on TENS and SBS need to use more patient-reported outcome measures and 
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functional goals and also investigate its use in spasticity involving multiple 
muscle groups. 
TENS is cost effective treatment option when delivered via 
commercially available stimulators. Although the initial cost of SBS would be 
higher than TENS we anticipate that it may be comparable in the long term as 
the stimulator and the electrode array are reusable (the hydrogel sheet is single 
patient use).  
Study limitations  
The limitations of this study are a small sample size and very short 
follow up period. Further randomised control trials should investigate long term 
application in order to evaluate any sustained effects on participants’ upper limb 
function. Participants should also be stratified based on different pathology and 
severity of symptoms, which was not practical with the limited size of this pilot 
study. 
Conclusions 
SBS results indicate a reduction in spasticity immediately after stimulation that 
persists for at least one hour. Further investigation of optimal stimulation 
parameters followed by larger and longer-term placebo controlled trials are 
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required before  firm conclusions can be made about the clinical value of the 
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